Patents by Inventor Thomas F. Tedder
Thomas F. Tedder has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20140065118Abstract: Provided herein are methods of expanding B cells, and in particularly B10 cells capable of producing IL-10, ex vivo. The methods include incubation of harvested B cells in the presence of IL-21. Compositions comprising the ex vivo expanded B cells and methods of using the expanded B cell-containing compositions to treat diseases or conditions are also provided. Methods of assessing B10 cell function in a subject are also provided.Type: ApplicationFiled: March 12, 2013Publication date: March 6, 2014Inventors: Thomas F. Tedder, Ayumi Yoshizaki, Tomomitsu Miyagaki, Evgueni Kountikov, Jonathan C. Poe
-
Publication number: 20140056896Abstract: The invention relates to immunotherapeutic compositions and methods for the treatment of B cell diseases and disorders in human subjects, such as, but not limited to, B cell malignancies and autoimmune diseases and disorders, using therapeutic antibodies that bind to the human CD19 antigen and that preferably mediate human ADCC. The present invention relates to pharmaceutical compositions comprising human or humanized anti-CD19 antibodies of the IgG1 or IgG3 human isotype. The present invention relates to pharmaceutical compositions comprising human or humanized anti-CD19 antibodies of the IgG2 or IgG4 human isotype that preferably mediate human ADCC. The present invention also relates to pharmaceutical compositions comprising chimerized anti-CD19 antibodies of the IgG1, IgG2, IgG3, or IgG4 isotype that mediate human ADCC. In preferred embodiments, the present invention relates to pharmaceutical compositions comprising monoclonal human, humanized, or chimeric anti-CD19 antibodies.Type: ApplicationFiled: August 1, 2013Publication date: February 27, 2014Applicant: DUKE UNIVERSITYInventors: Thomas F. Tedder, Yasuhito Hamaguchi, Hanne Gron, Norihito Yazawa
-
Publication number: 20130136754Abstract: The present invention relates to a distinct B cell subset, B10 cells, that regulate T cell mediated inflammatory responses through the secretion of interleukin-10 (IL-10). The invention also relates to the use of B10 cells in the manipulation of immune and inflammatory responses, and in the treatment of disease. Therapeutic approaches involving adoptive transfer of B10 cells, or expansion of their endogenous levels for controlling autoimmune or inflammatory diseases and conditions are described. Ablation of B10 cells, or inhibition of their IL-10 production can be used to upregulate immunodeficient conditions, ameliorate infectious diseases and/or to treat tumors/cancer. Diagnostic applications are also encompassed.Type: ApplicationFiled: August 4, 2011Publication date: May 30, 2013Inventors: Thomas F. Tedder, Takashi Matsushita, Yohei Iwata, Koichi Yanaba, Jean-David Bouaziz
-
Patent number: 8444973Abstract: The invention relates to immunotherapeutic compositions and methods for the treatment of B cell diseases and disorders in human subjects, such as, but not limited to, B cell malignancies and autoimmune diseases and disorders, using therapeutic antibodies that bind to the human CD19 antigen and that preferably mediate human ADCC. The present invention relates to pharmaceutical compositions comprising human or humanized anti-CD19 antibodies of the IgG1 or IgG3 human isotype. The present invention relates to pharmaceutical compositions comprising human or humanized anti-CD19 antibodies of the IgG2 or IgG4 human isotype that preferably mediate human ADCC. The present invention also relates to pharmaceutical compositions comprising chimerized anti-CD19 antibodies of the IgG1, IgG2, IgG3, or IgG4 isotype that mediate human ADCC. In preferred embodiments, the present invention relates to pharmaceutical compositions comprising monoclonal human, humanized, or chimeric anti-CD19 antibodies.Type: GrantFiled: September 17, 2010Date of Patent: May 21, 2013Assignee: Duke UniversityInventors: Thomas F. Tedder, Yasuhito Hamaguchi, Hanne Gron, Norihito Yazawa
-
Publication number: 20130084294Abstract: The invention relates to immunotherapeutic compositions and methods for the treatment of B cell diseases and disorders in human subjects, such as, but not limited to, B cell malignancies and autoimmune diseases and disorders, using therapeutic antibodies that bind to the human CD19 antigen and that preferably mediate human ADCC. The present invention relates to pharmaceutical compositions comprising human or humanized anti-CD19 antibodies of the IgG1 or IgG3 human isotype. The present invention relates to pharmaceutical compositions comprising human or humanized anti-CD19 antibodies of the IgG2 or IgG4 human isotype that preferably mediate human ADCC. The present invention also relates to pharmaceutical compositions comprising chimerized anti-CD19 antibodies of the IgG1, IgG2, IgG3, or IgG4 isotype that mediate human ADCC. In preferred embodiments, the present invention relates to pharmaceutical compositions comprising monoclonal human, humanized, or chimeric anti-CD19 antibodies.Type: ApplicationFiled: September 4, 2012Publication date: April 4, 2013Applicant: DUKE UNIVERSITYInventors: Thomas F. Tedder, Yasuhito Hamaguchi, Hanne Gron, Norihito Yazawa
-
Publication number: 20120301472Abstract: The invention concerns treatment methods using anti-CD22 monoclonal antibodies with unique physiologic properties. In particular, the invention concerns methods for the treatment of B-cell malignancies and autoimmune diseases by administering an effective amount of a blocking anti-CD22 monoclonal antibody specifically binding to the first two Ig-like domains, or to an epitope within the first two Ig-like domains of native human CD22 (hCD22).Type: ApplicationFiled: May 9, 2012Publication date: November 29, 2012Inventor: Thomas F. Tedder
-
Publication number: 20110135666Abstract: The present invention relates to a phenotypically distinct CD1dhigh CD5+ B cell subset that regulates T cell mediated inflammatory responses through the secretion of interleukin-10 (IL-IO). The invention also relates to the use of these IL-IO producing regulatory B cells in the manipulation of immune and inflammatory responses, and in the treatment of disease. Therapeutic approaches involving adoptive transfer of these regulatory B cells, or expansion of their endogenous levels for controlling autoimmune or inflammatory diseases and conditions are described. Ablation of this subset of regulatory B cells, or inhibition of their IL-IO production can be used to upregulate immunodeficient conditions, and/or to treat tumors/cancer. Diagnostic applications also are encompassed.Type: ApplicationFiled: April 27, 2009Publication date: June 9, 2011Inventors: Thomas F. Tedder, Koichi Yanaba, Jean-David Bouaziz
-
Publication number: 20110104150Abstract: The invention relates to immunotherapeutic compositions and methods for the treatment of B cell diseases and disorders in human subjects, such as, but not limited to, B cell malignancies and autoimmune diseases and disorders, using therapeutic antibodies that bind to the human CD19 antigen and that preferably mediate human ADCC. The present invention relates to pharmaceutical compositions comprising human or humanized anti-CD19 antibodies of the IgG1 or IgG3 human isotype. The present invention relates to pharmaceutical compositions comprising human or humanized anti-CD19 antibodies of the IgG2 or IgG4 human isotype that preferably mediate human ADCC. The present invention also relates to pharmaceutical compositions comprising chimerized anti-CD19 antibodies of the IgG1, IgG2, IgG3, or IgG4 isotype that mediate human ADCC. In preferred embodiments, the present invention relates to pharmaceutical compositions comprising monoclonal human, humanized, or chimeric anti-CD19 antibodies.Type: ApplicationFiled: September 17, 2010Publication date: May 5, 2011Applicant: DUKE UNIVERSITYInventors: Thomas F. Tedder, Yasuhito Hamaguchi, Hanne Gron, Norihito Yazawa
-
Publication number: 20100158901Abstract: The invention relates to immunotherapeutic compositions and methods for the treatment of autoimmune diseases and disorders in human subjects using therapeutic antibodies that bind to the human CD19 antigen and that preferably mediate human ADCC. The present invention relates to pharmaceutical compositions comprising human or humanized anti-CD19 antibodies of the IgG1 or IgG3 human isotype. The present invention relates to pharmaceutical compositions comprising human or humanized anti-CD19 antibodies of the IgG2 or IgG4 human isotype that preferably mediate human ADCC. The present invention also relates to pharmaceutical compositions comprising chimerized anti-CD19 antibodies of the IgG1, IgG2, IgG3, or IgG4 isotype that mediate human ADCC. In preferred embodiments, the present invention relates to pharmaceutical compositions comprising monoclonal human, humanized, or chimeric anti-CD19 antibodies.Type: ApplicationFiled: December 1, 2008Publication date: June 24, 2010Applicant: Duke UniversityInventors: Thomas F. Tedder, Yasuhito Hamaguchi, Hanne Gron, Norihito Yazawa
-
Publication number: 20090285808Abstract: The invention relates to immunotherapeutic compositions and methods for the treatment of B cell diseases and disorders in human subjects, such as, but not limited to, B cell malignancies, using therapeutic antibodies that bind to the human CD19 antigen and that preferably mediate human ADCC. The present invention relates to pharmaceutical compositions comprising human or humanized anti-CD19 antibodies of the IgG1 or IgG3 human isotype. The present invention relates to pharmaceutical compositions comprising human or humanized anti-CD19 antibodies of the IgG2 or IgG4 human isotype that preferably mediate human ADCC. The present invention also relates to pharmaceutical compositions comprising chimerized anti-CD19 antibodies of the IgG1, IgG2, IgG3, or IgG4 isotype that mediate human ADCC. In preferred embodiments, the present invention relates to pharmaceutical compositions comprising monoclonal human, humanized, or chimeric anti-CD19 antibodies.Type: ApplicationFiled: March 10, 2009Publication date: November 19, 2009Applicant: Duke UniversityInventors: Thomas F. Tedder, Yasuhito Hamaguchi, Hanne Gron, Norihito Yazawa
-
Publication number: 20090246195Abstract: The invention relates to immunotherapeutic compositions and methods for the treatment and prevention of GVHD, humoral rejection, and post-transplantation lymphoproliferative disorder in human subjects using therapeutic antibodies that bind to the human CD19 antigen and that preferably mediate human ADCC. The present invention relates to pharmaceutical compositions comprising human or humanized anti-CD19 antibodies of the IgG1 or IgG3 human isotype. The present invention relates to pharmaceutical compositions comprising human or humanized anti-CD19 antibodies of the IgG2 or IgG4 human isotype that preferably mediate human ADCC. The present invention also relates to pharmaceutical compositions comprising chimerized anti-CD19 antibodies of the IgG1, IgG2, IgG3, or IgG4 isotype that mediate human ADCC. In preferred embodiments, the present invention relates to pharmaceutical compositions comprising monoclonal human, humanized, or chimeric anti-CD19 antibodies.Type: ApplicationFiled: November 21, 2008Publication date: October 1, 2009Applicant: Duke UniversityInventor: Thomas F. Tedder
-
Publication number: 20090136516Abstract: The present invention provides monoclonal antibodies and antigen-binding fragments thereof that specifically bind to CD20, as well as pharmaceutical compositions comprising the same. The invention further provides methods of using the monoclonal antibodies, antigen-binding fragments, and pharmaceutical compositions, for example, in methods of depleting B cells or in treating B cell disorders. Also provided are cells, nucleic acids and methods for producing the monoclonal antibodies.Type: ApplicationFiled: May 7, 2004Publication date: May 28, 2009Inventors: Thomas F. Tedder, Junji Uchida, Yasuhito Hamaguchi, Jonathan C. Poe
-
Publication number: 20080118505Abstract: The invention concerns treatment methods using anti-CD22 monoclonal antibodies with unique physiologic properties. In particular, the invention concerns methods for the treatment of B-cell malignancies and autoimmune diseases by administering an effective amount of a blocking anti-CD22 monoclonal antibody specifically binding to the first two Ig-like domains, or to an epitope within the first two Ig-like domains of native human CD22 (hCD22).Type: ApplicationFiled: August 6, 2007Publication date: May 22, 2008Applicant: Duke UniversityInventor: Thomas F. Tedder
-
Patent number: 6921846Abstract: The subject invention relates a method for the production of monoclonal antibodies. The method utilizes an immunized animal having antibody-producing cells with disrupted peripheral tolerance. The invention also provides a method for the use of such monoclonal antibodies, and polyclonal antibodies derived from an immunized animal having antibody-producing cells with disrupted peripheral tolerance, for in vitro and in vivo clinical diagnostics and therapeutics.Type: GrantFiled: November 25, 1998Date of Patent: July 26, 2005Assignee: Duke UniversityInventor: Thomas F. Tedder
-
Publication number: 20040137566Abstract: Isolated nucleic acids encoding MS4A polypeptides; isolated MS4A polypeptides, and uses thereof. The disclosed MS4A nuclcic acids and polypeptides can be used to generate a mouse model of atopic disorders, for drug discovery screens, and for therapeutic treatment of atopic disorders or other MS4A-related conditions.Type: ApplicationFiled: September 30, 2003Publication date: July 15, 2004Inventor: Thomas F. Tedder
-
Publication number: 20040001828Abstract: The invention concerns treatment methods using anti-CD22 monoclonal antibodies with unique physiologic properties. In particular, the invention concerns methods for the treatment of B-cell malignancies by administering an effective amount of a blocking anti-CD22 monoclonal antibody specifically binding to the first two Ig-like domains, or to an epitope within the first two Ig-like domains of native human CD22 (hCD22).Type: ApplicationFiled: February 21, 2003Publication date: January 1, 2004Inventors: Joseph Tuscano, Thomas F. Tedder
-
Publication number: 20030202975Abstract: The invention concerns treatment methods using anti-CD22 monoclonal antibodies with unique physiologic properties. In particular, the invention concerns methods for the treatment of B-cell malignancies and autoimmune diseases by administering an effective amount of a blocking anti-CD22 monoclonal antibody specifically binding to the first two Ig-like domains, or to an epitope within the first two Ig-like domains of native human CD22 (hCD22).Type: ApplicationFiled: February 21, 2003Publication date: October 30, 2003Inventor: Thomas F. Tedder
-
Patent number: 6451981Abstract: Human lymphocyte-associated cell surface protein LAM-1, which includes domains homologous with binding domains of animal lectins, growth factors, and C3/C4 binding proteins, and the cDNA encoding LAM-1, are described. Antagonists to LAM-1 are used in a method of treating a human patient suffering from a lymphocyte-mobilizing condition which involves administering a therapeutic amount of the antagonist in a non-toxic pharmaceutical carrier substance. Additionally, antibodies that bind human LAM-1 and inhibit cellular adhesion, migration or infiltration into tissues are described.Type: GrantFiled: June 2, 1995Date of Patent: September 17, 2002Assignee: Dana-Farber Cancer InstituteInventor: Thomas F. Tedder
-
Patent number: 6274347Abstract: A shed form of leukocyte adhesion molecule-1 (LAM-1, L-selectin) is present in high levels in human plasma. Quantitative methods of detecting shed LAM-1 (sLAM-1) by Western blot and ELISA analysis are disclosed. Also disclosed are methods for the specific detection of cell-surface bound LAM-1 in the presence of shed LAM-1 and for immunotherapy using monoclonal antibodies reactive with cell-surface bound LAM-1 but not reactive with shed LAM-1. In addition a method of producing an antibody that is reactive with cell-surface bound LAM-1 but not reactive with shed LAM-1 is disclosed.Type: GrantFiled: January 17, 1997Date of Patent: August 14, 2001Assignee: Dana-Farber Cancer Institute, Inc.Inventors: Thomas F. Tedder, Boris Schleiffenbaum, Olivier Spertini
-
Patent number: 6020152Abstract: A human cDNA sequence encoding lymphocyte-associated cell surface protein LAM-1, which contains domains homologous with binding domains of animal lectins, growth factors, and C3/C4 binding proteins, and the LAM-1 protein encoded by the cDNA sequence, are described. Antagonists to LAM-1 are used in a method of treating a human patient suffering from a lymphocyte-mobilizing condition which involves administering a therapeutic amount of the antagonist in a non-tox pharmaceutical carrier substance.Type: GrantFiled: March 24, 1993Date of Patent: February 1, 2000Assignee: Dana-Farber Cancer Institute, Inc.Inventor: Thomas F. Tedder